Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss strategies to address PARP inhibitor (PARPi) resistance in ovarian cancer, including emerging combinations like gotistobart + pembrolizumab from the PRESERVE-004 trial, insights from the SOPRANO trial on managing oligometastases or oligoprogression, and approaches to mitigate or manage common adverse events associated with PARPi maintenance therapy.

EP: 1.Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP: 2.Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

EP: 3.Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

EP: 4.Emerging Combinations in Maintenance Therapy for Ovarian Cancer

Now Viewing

EP: 5.Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

EP: 6.Use of Trastuzumab Deruxtecan in Ovarian Cancer

EP: 7.Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

EP: 8.Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches

Video content above is prompted by the following:

Please comment on PARP inhibitor (PARPi) resistance. Are there promising strategies to overcome this challenge?
PRESERVE-004 gotistobart + pembrolizumab
Others?
What insights can be drawn from the SOPRANO trial findings regarding the management of oligometastases or oligoprogression in ovarian cancer?
What adverse events are most commonly seen with PARPi maintenance therapy and how do you mitigate or manage these?